Suzuki M, Mishima H K, Masuda K, Araie M, Kitazawa Y, Azuma I
Department of Ophthalmology, Hiroshima University School of Medicine, Japan.
Jpn J Ophthalmol. 2000 Jan-Feb;44(1):33-8. doi: 10.1016/s0021-5155(99)00147-1.
To evaluate the intraocular pressure (IOP)-lowering effect and safety of latanoprost, a prostaglandin analogue, in patients with primary open-angle glaucoma or ocular hypertension.
One hundred and twenty-four Japanese patients with primary open-angle glaucoma or ocular hypertension were enrolled in this open-labeled study and were treated with 0.005% latanoprost once daily for 1 year.
At all follow-up visits there was a significant (P < .001) reduction in IOP compared with the baseline value. After 1 year, the IOP was reduced by 5.4 +/- 2.9 (mean +/- SD) mm Hg from a baseline value of 23.5 +/- 2.2 mm Hg. No evidence of an upward drift in the IOP was observed during the treatment period. The most frequently reported adverse ocular events were mild conjunctival hyperemia and iris pigmentation. Very few adverse systemic events were observed.
Latanoprost eye drops showed a marked and stable IOP-lowering effect during the 1-year treatment period. Furthermore, latanoprost was well-tolerated and should be a valuable contribution to the management of glaucoma.
评估前列腺素类似物拉坦前列素对原发性开角型青光眼或高眼压症患者的降眼压效果及安全性。
124例日本原发性开角型青光眼或高眼压症患者纳入这项开放标签研究，接受0.005%拉坦前列素每日一次治疗，为期1年。
在所有随访中，与基线值相比眼压均显著降低（P <.001）。1年后，眼压从基线值23.5±2.2毫米汞柱降低了5.4±2.9（均值±标准差）毫米汞柱。治疗期间未观察到眼压上升趋势。最常报告的眼部不良事件是轻度结膜充血和虹膜色素沉着。观察到的全身不良事件极少。
拉坦前列素滴眼液在1年治疗期内显示出显著且稳定的降眼压效果。此外，拉坦前列素耐受性良好，对青光眼治疗应具有重要价值。
